Kiniksa Pharmaceuticals International, plc
KNSA
$56.51
-$2.03-3.47%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.01% | 11.76% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.01% | 11.76% | |||
| Cost of Revenue | 5.93% | 8.87% | |||
| Gross Profit | 6.06% | 14.25% | |||
| SG&A Expenses | 7.71% | 15.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.45% | 16.28% | |||
| Operating Income | 48.05% | -17.71% | |||
| Income Before Tax | 40.45% | -14.32% | |||
| Income Tax Expenses | 11.23% | 3.99% | |||
| Earnings from Continuing Operations | 59.11% | -22.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 59.11% | -22.98% | |||
| EBIT | 48.05% | -17.71% | |||
| EBITDA | 46.95% | -17.09% | |||
| EPS Basic | 58.00% | -24.24% | |||
| Normalized Basic EPS | 39.45% | -15.76% | |||
| EPS Diluted | 49.25% | -21.35% | |||
| Normalized Diluted EPS | 39.04% | -15.94% | |||
| Average Basic Shares Outstanding | 0.72% | 1.68% | |||
| Average Diluted Shares Outstanding | 1.03% | 1.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||